Microdosing Amanita muscaria for Health & Longevity - Quick Reference Sheet

Microdosing Amanita muscaria for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Microdosing Amanita muscaria means repeated small doses of fly agaric, a red-capped, white-spotted mushroom sold dried, as liquid, capsules, or gummies, for stress, sleep, and mood. No human trial with a comparison group has tested it for health or longevity; benefit signals are weak, indirect, and sometimes conflicting. Documented harms come from poison-center records and product testing; products are often mislabeled or contaminated. Safety at very small doses is unknown. (Full Review)

Protocol

Community regimen
0.1-0.5 g dried, heat-converted cap
0.5 g called cautious, or tincture from about 5 drops daily; no clinician-validated or trial-tested protocol exists
Competing forms
Dried cap, tincture or extract, gummy or capsule
None is a default; a standardized extract contained negligible ibotenic acid and muscimol, so form changes exposure
Single versus split doses
One daily dose in reported regimens
Split dosing is untested, and slow onset makes repeat dosing risky
Time to effect
Sustained benefit
Unknown
Time to any sustained benefit at microdose levels is unknown; no controlled study exists
Acute effects onset
30 minutes to 2 hours
After ingestion
Acute effects duration
6-8 hours
At intoxicating doses; no human half-life is established

Benefits

Contraindications
  • Benzodiazepines and Z-drugs (alprazolam, lorazepam, zolpidem)
  • Opioids and gabapentinoids (oxycodone, morphine, gabapentin, pregabalin)
  • Alcohol and other psychoactive substances (psilocybin, diazepam, zolpidem)
  • Pregnant or breastfeeding individuals
  • People under 18 years
  • People with seizure disorders or a history of seizures
  • People with psychotic disorders, a history of bipolar mania, or a first-degree relative with schizophrenia
  • People with severe kidney impairment (eGFR below 30 mL/min/1.73 m²) or severe liver impairment
  • People with severe respiratory disease or untreated sleep apnea
  • People with symptomatic bradycardia (slow heart rate, below 50 beats per minute)
  • Anyone driving or operating machinery within 8 hours of dosing
Key Interactions
  • Barbiturates and antiseizure drugs (phenobarbital, valproate; caution)
  • Antipsychotics (olanzapine, quetiapine, haloperidol; caution)
  • Cholinergic and rate-slowing drugs (pilocarpine, donepezil, metoprolol, diltiazem; monitor)
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine; caution)
  • Supplements with GABA-like action (kava, valerian, phenibut; caution)
  • Cannabinoids (THC, cannabidiol; caution)

Risk & Side Effects

  • High:
  • Medium: Acute intoxication with neurological and respiratory effects, contaminated, mislabeled, or inconsistent products
  • Low: Prolonged or delayed psychiatric effects, cholinergic symptoms from muscarine, tolerance, dependence, and withdrawal
  • Speculative: Heavy-metal accumulation, neuroinflammation, ibotenic acid neurotoxicity

Monitoring

Marker Target Why
Liver enzymes (ALT, AST) 10-26 U/L each Baseline reserve; rules out liver injury from contaminants or misidentified mushrooms
Kidney function (creatinine, eGFR) Creatinine 0.7-1.0 mg/dL; eGFR above 90 mL/min/1.73 m² Both compounds are cleared by the kidneys
Blood lead Below 2 µg/dL Mushrooms accumulate lead
Blood cadmium Below 0.5 µg/L Mushrooms accumulate cadmium
Resting heart rate and blood pressure 50-70 beats per minute; below 120/80 mmHg Muscarine may slow heart rate; sedatives may lower blood pressure
Wearable-tracked sleep No established target; change from own baseline in total sleep time and awakenings Tests whether a claimed sleep benefit is real

Cadence: Baseline first, including 2-4 weeks of sleep tracking; sleep and symptom scores weekly for the first month, heart rate and blood pressure at 1 and 4 weeks, liver and kidney panels at 3 months, then every 6-12 months, with metals repeated yearly or whenever the product or supplier changes

Qualitative Assessment

  • Sleep quality and morning alertness
  • Anxiety and mood on validated scales (PHQ-9 depression scale, GAD-7 anxiety scale)
  • Next-day drowsiness, coordination, and dream disturbance
  • Nausea, headache, salivation, or sweating